Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$555M |
| 2 |
Citigroup
C
|
+$407M |
| 3 |
Medtronic
MDT
|
+$401M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$392M |
| 5 |
Gilead Sciences
GILD
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.43B |
| 2 |
Amazon
AMZN
|
+$1.32B |
| 3 |
Apple
AAPL
|
+$1.1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$995M |
| 5 |
Bank of America
BAC
|
+$726M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.47% |
| 2 | Technology | 3.02% |
| 3 | Healthcare | 2.92% |
| 4 | Consumer Discretionary | 2.17% |
| 5 | Financials | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
OMGA
14026
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $60 | ﹤0.01% |
49
-1,033,086
| -100% | -$1.64M |
2024 Q1
2 quarters
|
|
|
RGLS
14027
DELISTED
Regulus Therapeutics
RGLS
| $50 | ﹤0.01% |
+32
| New | +$53 |
2024 Q3
0 quarters
|
|
|
EDVA
14028
PUT
Endovia Health Sciences, Inc.
EDVA
$1.1M
| $50 | ﹤0.01% |
1
-4
| -80% | -$201 |
2022 Q3
8 quarters
|
|
14029
Vanguard FTSE Emerging Markets ETF
VWO
$125B
| $48 | ﹤0.01% |
1
-1,122,962
| -100% | -$50M |
2024 Q1
2 quarters
|
|
|
BROGW
14030
DELISTED
Brooge Holdings Limited Warrant expiring 12/20/2024
BROGW
| $48 | ﹤0.01% |
11,952
+695
| +6% | +$3 |
2023 Q3
4 quarters
|
|
14031
Actinium Pharmaceuticals
ATNM
$36.8M
| $43 | ﹤0.01% |
23
-65,454
| -100% | -$259K |
2022 Q1
10 quarters
|
|
14032
PUT
Kaixin Holdings
KXIN
$62.5M
| – | – |
0
| – | – |
2023 Q4
3 quarters
|
|
|
OGI
14033
Organigram Holdings
OGI
$137M
| $38 | ﹤0.01% |
21
-28,954
| -100% | -$50.4K |
2024 Q2
1 quarter
|
|
14034
Pacific Biosciences
PACB
$790M
| $37 | ﹤0.01% |
22
-904,179
| -100% | -$1.49M |
2015 Q3
36 quarters
|
|
14035
Achieve Life Sciences
ACHV
$746M
| $28 | ﹤0.01% |
+6
| New | +$27 |
2024 Q3
0 quarters
|
|
|
ENSV
14036
PUT
DELISTED
Enservco Corp.
ENSV
| $26 | ﹤0.01% |
+200
| New | +$34 |
2024 Q3
0 quarters
|
|
|
SANW
14037
PUT
DELISTED
S&W Seed Co
SANW
| $19 | ﹤0.01% |
5
| – | – |
2024 Q2
1 quarter
|
|
14038
Energy Fuels
UUUU
$2.84B
| $16 | ﹤0.01% |
3
-224,721
| -100% | -$1.17M |
2018 Q2
25 quarters
|
|
14039
Gran Tierra Energy
GTE
$369M
| $13 | ﹤0.01% |
2
-1,049
| -100% | -$8.41K |
2021 Q1
14 quarters
|
|
14040
Vivani Medical
VANI
$111M
| $9 | ﹤0.01% |
+8
| New | +$10 |
2024 Q3
0 quarters
|
|
|
KNDI
14041
Kandi Technologies Group
KNDI
$82.4M
| $6 | ﹤0.01% |
3
-97
| -97% | -$176 |
2021 Q1
14 quarters
|
|
|
AACG
14042
ATA Creativity
AACG
$33.3M
| – | – |
-50,580
| Closed | -$39.5K | – |
|
14043
CALL
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$4.02B
| – | – |
-4,200
| Closed | -$302K | – |
|
|
14044
PUT
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$4.02B
| – | – |
-500
| Closed | -$36K | – |
|
14045
Alpha Blue Capital US Small-Mid Cap Dynamic ETF
ABCS
$12.4M
| – | – |
-7,701
| Closed | -$200K | – |
|
14046
Ambev
ABEV
$46.1B
| – | – |
-762,194
| Closed | -$1.71M | – |
|
14047
Absci
ABSI
$1.9B
| – | – |
-846,826
| Closed | -$3.37M | – |
|
14048
ABVC BioPharma
ABVC
$27M
| – | – |
-25,212
| Closed | -$19.5K | – |
|
14049
Aclarion
ACON
$6.86M
| – | – |
-3
| Closed | -$8.24K | – |
|
|
ACTV
14050
DELISTED
LeaderShares Activist Leaders ETF
ACTV
| – | – |
-9,079
| Closed | -$291K | – |
|
Similar funds
Citadel Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Citadel Advisors held 15,731 positions worth $518B, up 4.9% from $494B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Citadel Advisors's Q3 2024 filing shows 1,612 new, 6,434 increased, 5,866 reduced and 1,610 closed positions. Its largest new stake was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M. The largest sale was Invesco QQQ Trust, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 82% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q3 2024 buy was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M.
- Citadel Advisors added most to NVIDIA in Q3 2024, an estimated $555M increase.
- Citadel Advisors's biggest Q3 2024 reduction was Invesco QQQ Trust, cutting an estimated $1.43B.
- Citadel Advisors fully exited Domino's in Q3 2024, selling an estimated $186M.
- Citadel Advisors's ten largest holdings make up 30% of its $518B portfolio in Q3 2024.
- Citadel Advisors opened 1,612 new positions and closed 1,610 in Q3 2024.
- Citadel Advisors's portfolio value rose 4.9% quarter-over-quarter to $518B.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.